Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) EBT Margin (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed EBT Margin for 17 consecutive years, with 0.99% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 410.0% to 0.99% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 34.46% through Dec 2025, down 3333.0% year-over-year, with the annual reading at 34.46% for FY2025, 3333.0% down from the prior year.
  • EBT Margin hit 0.99% in Q4 2025 for Integra Lifesciences Holdings, up from 1.7% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 18.68% in Q1 2021 to a low of 127.75% in Q2 2025.
  • Historically, EBT Margin has averaged 0.49% across 5 years, with a median of 6.18% in 2023.
  • Biggest five-year swings in EBT Margin: skyrocketed 1546bps in 2021 and later tumbled -12412bps in 2025.
  • Year by year, EBT Margin stood at 12.77% in 2021, then rose by 26bps to 16.13% in 2022, then plummeted by -55bps to 7.27% in 2023, then decreased by -30bps to 5.09% in 2024, then tumbled by -81bps to 0.99% in 2025.
  • Business Quant data shows EBT Margin for IART at 0.99% in Q4 2025, 1.7% in Q3 2025, and 127.75% in Q2 2025.